AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway in July 2020, except in Japan where Daiichi Sankyo maintains ...

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Whereas Daiichi Sankyo Company Limited (OTC:DSNKY) manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally.

Enriqueta Felip Consulting or Advisory Role: AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Roche, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, ...

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Hiroyuki Okuzawa ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer Approximately 557,000 people are diagnosed with breast cancer every year in Europe AstraZeneca (AZ) and Daiichi Sankyo’s ...

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe The questionnaire gathered insights from 7,750 adults across five countries A new European survey sponsored by ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...